Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

AIDS

Volumn 15, Issue 11, 2001, Pages 1359-1368

  Birk, Markus ^a   Svedhem, Veronica ^a   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral therapy; Drug resistance; HIV 1; Rebound; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MYOPATHY; NEPHROLITHIASIS; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRUCTURAL GENE; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; VIRAL LOAD;

EID: 0035958763     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00005     Document Type: Article

References (36)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
2. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators
3. Decay characteristics of HIV-1-infected compartments during combination therapy
4. Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy
5. HIV-1 rebound after anti-retroviral therapy
6. Re-emergence of HIV after stopping therapy
7. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
8. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
9. Hidden dangers of incompletely supressive antiretroviral therapy
10. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
11. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
12. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
13. Drug resistance during Indinavir therapy is caused by mutations in the protease gene and its gag substrate cleaving sites
14. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
15. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
16. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy
17. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains
18. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
19. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
20. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine
21. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
22. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
23. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
24. Immune control of HIV-1 after early treatment of acute infection
25. Viral dynamics of acute HIV-1 infection
26. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
27. Control of HIV despite the discontinuation of antiretroviral therapy
28. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
29. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
30. Revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescent and adults
31. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users
32. Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART
33. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
34. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates
35. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera
36. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure